Skip to main content

Table 2 Characteristics of samples

From: Predicting polypharmacy in half a million adults in the Iranian population: comparison of machine learning algorithms

Variable

Total

(n = 554 133)

Polypharmacy

No

(n = 354 648)

Yes

(n = 199 485)

Socio-demographic

Age (year); Median (IQR)

51 (40 – 62) yr

51 (39 – 61) yr

52 (41 – 63) yr

Gender

 Female

346 569 (62.5%)

221 554 (62.5%)

125 015 (62.7%)

 Male

207 564 (37.5%)

133 094 (37.5%)

74 470 (37.3%)

Marital status

 Single

202 258 (36.5%)

131 574 (37.1%)

70 684 (35.4%)

 Married

351 875 (63.5%)

226 265 (63.8%)

125 610 (63.0%)

Employment status

 Employed

461 039 (83.2%)

294 358 (83.0%)

166 681 (83.6%)

 Unemployed

93 094 (16.8%)

61 354 (17.1%)

31 740 (15.9%)

Income

 Low

231 384 (41.8%)

148 598 (41.9%)

82 786 (41.5%)

 Middle

193 578 (34.9%)

123 559 (34.8%)

70 019 (35.1%)

 High

129 312 (23.3%)

82 633 (23.3%)

46 679 (23.4%)

Residence area

 Urban

434 839 (78.5%)

278 044 (78.4%)

156 795 (78.6%)

 Rural

119 294 (21.5%)

76 604 (21.6%)

42 690 (21.4%)

Ethnicity

 Arab

184 614 (33.3%)

117 388 (33.1%)

67 226 (33.7%)

 Fars

179 450 (32.4%)

115 615 (32.6%)

63 835 (32.0%)

 Lor

167 548 (30.2%)

107 104 (30.2%)

60 444 (30.3%)

 Tork & Kord

22 521 (4.1%)

14 541 (4.1%)

7 980 (4.0%)

Prescriptions

Season

 Spring

132 991 (24.0%)

85 115 (24.0%)

47 876 (24.0%)

 Summer

131 130 (23.7%)

84 052 (23.7%)

47 078 (23.6%)

 Autumn

146 491 (26.4%)

93 627 (26.4%)

52 864 (26.5%)

 Winter

143 521 (25.9%)

91 854 (25.9%)

51 667 (25.9%)

TPS $; Median (IQR), per persc/y

4.4 (2.1 – 10.3) $

2.9 (1.5 – 6.7) $

7.7 (4.4 – 14.8) $

NOP; Median (IQR), per year

2.7 (1.4 – 4.3)

2.6 (1.4 – 4.3)

2.7 (1.5 – 4.4)

NOD; Median (IQR), per persc/y

4.7 (2.1 – 6.4)

3.8 (2.5 – 5.6)

4.2 (3.7 – 7.1)

ICPD $; Median (IQR), per persc/y

1.3 (0.9 – 1.8)$

1.3 (0.9 – 1.8)$

1.4 (0.9 – 1.9)$

NVGP; Median (IQR), per year

2.2 (1.4 – 4.6)

2.1 (2.0 – 3.9)

2.2 (2.0 – 4.1)

NVS; Median (IQR), per year

2.3 (1.5 – 4.7)

2.2 (1.9 – 3.7)

2.3 (2.1 – 4.1)

Comorbidity

Any comorbidity

169 942 (30.7%)

107 104 (30.2%)

62 838 (31.5%)

DM

47 943 (8.7%)

29 790 (8.4%)

18 153 (9.1%)

Asthma

46 592 (8.4%)

29 436 (8.3%)

17 156 (8.6%)

DLP

363 135 (65.5%)

230 876 (65.1%)

132 259 (66.3%)

HTN

209 751 (37.9%)

130 156 (36.7%)

79 595 (39.9%)

GERD

239 518 (43.2%)

152 144 (42.9%)

87 374 (43.7%)

CVD

30 699 (5.5%)

17 732 (5.0%)

12 967 (6.9%)

CKD

47 079 (8.5%)

28 726 (8.1%)

18 353 (9.2%)

RA

4 581 (0.8%)

2 766 (0.8%)

1 815 (0.9%)

MHC

119 892 (21.6%)

76 604 (21.6%)

43 288 (21.7%)

  1. TPS total pharmaceutical spending, NOP number of prescriptions, NOD number of drugs, ICPD insurance coverage for prescription drugs, NVGP number of visits to the general practitioner, NVS number of visits to a specialist, DM diabetes mellitus, DLP dyslipidemia, HTN hypertension, GERD gastrointestinal reflux disease, CVD cardiovascular diseases, CKD chronic kidney disease, RA rheumatoid arthritis, MHC mental health conditions